RELIABLY GO DEEP With the first and only FDA-authorized BCR-ABL test for the precise monitoring of deep molecular response in CML patients entering Treatment-free Remission* Optimized workflow, utilizing a one-step RT-qPCR method Reduced complexity with software reporting on the International Scale (IS) Proven sensitivity to MR4.5 through the use of plate controls Demonstrated performance with greater than 10,000 data points spanning over five years of on-going clinical trial testing associated with Treatment-free Remission The MRDx® Companion Diagnostic Test The MRDx® Test is intended for initiating and monitoring Treatment-free Remission in patients treated with Tasigna®. For more information: www.mrdxtest.com getmrdx@molecularmd.com 866-GET-MRDX (438-6739) * Treatment-free Remission eligible Ph+ CML patients being treated with Tasigna®. Refer to prescribing information in the Tasigna® package insert. © 2018 MolecularMD. All rights reserved. MRDx is a registered trademark of MolecularMD. Tasigna is a registered trademark of Novartis AG.http://www.mrdxtest.com http://molecularmd.com/